ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.70M
Average 1.06M
Big Five Numbers
ADARx Pharmaceuticals, Inc. growth analysis
Start with the long-run numbers that show whether ADRX compounds: return on capital and growth in sales, earnings, equity, and free cash flow.
Growth analysis
Is growth accelerating or fading?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
Revenue segments
Where does the growth come from?
Break revenue down by product and geography to see which parts of the business drive the trend.
Revenue by segment
Where ADRX earns its revenue, as reported in company filings
This company does not report revenue segments.
Free cash flow
Does growth turn into cash?
Check whether reported growth converts into free cash flow after capital spending.
Free Cash Flow
Net Income to FCF bridge
No cash flow data available.
Price targets
What do analysts expect from the price?
Compare the current price with the low, average, and high analyst targets.
Wall Street price targets
1-year price history with analyst consensus target
Unlock analyst target range
Sign in free to see low, average, high targets and implied upside for ADRX.
Analyst ratings
How do analysts rate the stock?
Review the buy, hold, and sell split and recent upgrades and downgrades.
Analyst ratings
Buy, hold, and sell recommendations and recent rating changes
Unlock analyst ratings
Sign in free to see the buy/hold/sell breakdown and recent rating changes for ADRX.
Competitor growth
How does ADARx Pharmaceuticals, Inc. grow against peers?
Compare historical and forecast growth with similar companies.
Competitor Growth
Peer CAGR comparison & forward estimates
| Company | Market Cap | 10yr | 5yr | 3yr | Fwd |
|---|---|---|---|---|---|
Stoke Therapeutics, Inc. STOK | $1.75B | — | — | +145.9% | +27.1% (5yr)5 analysts |
Silence Therapeutics plc SLN | $936.65M | — | -36.7% | -68.4% | +213.7% (5yr)3 analysts |
MeiraGTx Holdings plc MGTX | $881.67M | — | +39.2% | +72.3% | +48.6% (5yr)2 analysts |
Prime Medicine, Inc. PRME | $774.48M | — | -2.3% | — | +87.0% (5yr)5 analysts |
Wave Life Sciences Ltd. WVE | $617.33M | +75.7% | +16.3% | +127.1% | +53.3% (5yr)9 analysts |
Benitec Biopharma Inc. BNTC | $315.40M | — | — | — | —1 analysts |
Arcturus Therapeutics Holdings Inc. ARCT | $240.96M | +27.0% | +47.8% | -31.1% | +37.7% (5yr)5 analysts |
ProQR Therapeutics N.V. PRQR | $198.98M | +5.0% | +71.5% | +62.0% | +48.5% (5yr)2 analysts |
Atrium Therapeutics, Inc. RNA | $128.46M | — | — | — | +0.0% (5yr)2 analysts |
Questions
Growth questions
Common questions about ADRX's growth, answered from reported and forecast figures.
Continue the stock analysis
Jump to another research area for this company.